BroxyquinolineCAS# 521-74-4 |
- RVX-208
Catalog No.:BCC4475
CAS No.:1044870-39-4
- Bromodomain Inhibitor, (+)-JQ1
Catalog No.:BCC1132
CAS No.:1268524-70-4
- CPI-203
Catalog No.:BCC4099
CAS No.:1446144-04-2
- BET-BAY 002
Catalog No.:BCC5510
CAS No.:1588521-78-1
- SGC-CBP30
Catalog No.:BCC2419
CAS No.:1613695-14-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 521-74-4 | SDF | Download SDF |
| PubChem ID | 2453 | Appearance | Powder |
| Formula | C9H5Br2NO | M.Wt | 302.95 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 33.33 mg/mL (110.02 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | 5,7-dibromoquinolin-8-ol | ||
| SMILES | C1=CC2=C(C(=C(C=C2Br)Br)O)N=C1 | ||
| Standard InChIKey | ZDASUJMDVPTNTF-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C9H5Br2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Broxyquinoline Dilution Calculator
Broxyquinoline Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.3009 mL | 16.5044 mL | 33.0087 mL | 66.0175 mL | 82.5219 mL |
| 5 mM | 0.6602 mL | 3.3009 mL | 6.6017 mL | 13.2035 mL | 16.5044 mL |
| 10 mM | 0.3301 mL | 1.6504 mL | 3.3009 mL | 6.6017 mL | 8.2522 mL |
| 50 mM | 0.066 mL | 0.3301 mL | 0.6602 mL | 1.3203 mL | 1.6504 mL |
| 100 mM | 0.033 mL | 0.165 mL | 0.3301 mL | 0.6602 mL | 0.8252 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Broxyquinoline is an antiprotozoal agent and able to release oxygen free radicals from the water in mucous membranes.
- Cinnamoylcocaine
Catalog No.:BCN1429
CAS No.:521-67-5
- Frangulin A
Catalog No.:BCC8174
CAS No.:521-62-0
- Physcion
Catalog No.:BCN5663
CAS No.:521-61-9
- Vulpic acid
Catalog No.:BCN6546
CAS No.:521-52-8
- Pedicin
Catalog No.:BCN4845
CAS No.:521-51-7
- Cannabinol
Catalog No.:BCN7968
CAS No.:521-35-7
- Sciadopitysin
Catalog No.:BCN5662
CAS No.:521-34-6
- Bilobetin
Catalog No.:BCN5661
CAS No.:521-32-4
- Stanolone
Catalog No.:BCC9153
CAS No.:521-18-6
- Androstenediol
Catalog No.:BCC8828
CAS No.:521-17-5
- Dromostanolone propionate
Catalog No.:BCC8954
CAS No.:521-12-0
- Mestanolone
Catalog No.:BCC9022
CAS No.:521-11-9
- Karanjin
Catalog No.:BCN8370
CAS No.:521-88-0
- 2,4-Dihydroxy-6-methoxy-3-formylacetophenone
Catalog No.:BCN1430
CAS No.:52117-67-6
- 3-O-Acetylpinobanksin
Catalog No.:BCN5660
CAS No.:52117-69-8
- H-Tyr(Bzl)-OBzl.HCl
Catalog No.:BCC3131
CAS No.:52142-01-5
- Piperitol
Catalog No.:BCN3968
CAS No.:52151-92-5
- 7-Hydroxy-2,3,4,5-tetrahydro-1H-benzofuro[2,3-c]azepin-1-one
Catalog No.:BCC3960
CAS No.:521937-07-5
- N'-Methylammodendrine
Catalog No.:BCN2147
CAS No.:52196-10-8
- Evoxine
Catalog No.:BCN5664
CAS No.:522-11-2
- Quercitrin
Catalog No.:BCN5665
CAS No.:522-12-3
- Deguelin
Catalog No.:BCN4804
CAS No.:522-17-8
- Norsanguinarine
Catalog No.:BCN3714
CAS No.:522-30-5
- Lochnerine
Catalog No.:BCN5667
CAS No.:522-47-4
A study on the neurotoxicity of broxyquinoline and brobenzoxaldine combination in therapeutic doses.[Pubmed:3081428]
Hum Toxicol. 1986 Jan;5(1):35-41.
The neurotoxicity of a combination of Broxyquinoline and brobenzoxaldine (Intestopan Forte, containing 500 mg and 100 mg of the drugs respectively per capsule) was investigated by prospective clinical and electrophysiological studies in patients and volunteer subjects given the drugs in therapeutic doses (two capsules three times a day for 5 days). Of 16 patients with intestinal amoebiasis given the drugs (study A), 13 (81.25%) were cured. Adverse effects were mild and did not affect treatment. No neurological adverse effect was reported. Neurological examinations revealed no abnormality in any patient after treatment. Seven volunteer subjects underwent medical, neurological and ophthalmological examinations, and electrophysiological studies of ulnar and peroneal nerve conduction before and after treatment with the drugs in therapeutic doses (study B). Transient paresthesias were reported by one subject on the fourth day of treatment. No medical, neurological or ophthalmological abnormality was detected in any subject after treatment. There was no significant change in motor nerve conduction velocities. There was a significant (P less than 0.001) increase in the stimulus strength for distal ulnar stimulation and a significant (P less than 0.01) decrease in stimulus duration for proximal and distal ulnar stimulation. No significant changes were seen in the peroneal nerves in these parameters. No qualitative abnormality was seen in the oscilloscopic patterns of nerve conduction after treatment. Literature on the neurotoxicity of the halogenated hydroxyquinolines is reviewed. It is concluded that Broxyquinoline and brobenzoxaldine (and probably other halogenated hydroxyquinolines as well) are safe and effective in therapeutic doses; neurotoxicity is unlikely to occur when these drugs are used according to therapeutic recommendations.
Impairment of exercise tolerance due to broxyquinoline-brobenzoxaldine combination.[Pubmed:3081430]
Hum Toxicol. 1986 Jan;5(1):63-4.
A case report of impaired exercise tolerance during administration of Broxyquinoline-brobenzoxaldine combination in therapeutic doses is presented. The first author of this paper, a 28-year-old healthy male, volunteered as a subject for a prospective study on the neurotoxicity of halogenated hydroxyquinolines and took a course of Broxyquinoline-brobenzoxaldine combination. The author, who is a karate enthusiast, observed impairment of exercise tolerance during the course of treatment with the drugs. A challenge course of treatment with the same drugs in the same doses produced similar effects. Since halogenated hydroxyquinolines are still used widely in many countries, such an adverse effect would be of practical relevance, particularly in asymptomatic cyst-passers of Entamoeba histolytica whose occupations involve physical labour.
